Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Cencora (NYSE:COR) has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company. The agreement focuses on market access and distribution support for FDA approved CAR T cell therapies across U.S. treatment centers. The collaboration is aimed at easing logistical and administrative hurdles for healthcare providers using these personalized cancer treatments.

Cencora comes into this Kite agreement with a mixed share price record. The stock is trading at $279.57, with returns up 5.6% over the past week and 7.1% over the past 30 days, while the year-to-date move shows a decline of 17.5%. Over longer periods, returns of 59.6% over 3 years and 147.3% over 5 years show how much the stock has moved over time.

For investors tracking NYSE:COR, this partnership highlights Cencora’s role in the growing area of complex therapies and specialized distribution. The deal may influence how the market views Cencora’s position in next generation treatment logistics and its relationships with large biopharma partners.

Stay updated on the most important news stories for Cencora by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Cencora.NYSE:COR Earnings & Revenue Growth as at Jun 2026

5 things going right for Cencora that this headline doesn't cover.

Investor Checklist

Quick Assessment

✅ Price vs Analyst Target: At US$279.57, the stock sits about 25% below the US$350.58 analyst consensus target. ✅ Simply Wall St Valuation: Shares are flagged as undervalued, trading 42.6% below the platform's estimated fair value. ✅ Recent Momentum: The price is up 7.1% over the past 30 days, showing short term strength as this Kite deal lands.

There's only one way to know the right time to buy, sell or hold Cencora. Head to Simply Wall St's company report for the latest analysis of Cencora's Fair Value.

Key Considerations

📊 The Kite CAR T partnership reinforces Cencora’s role in complex therapy distribution. This may be important for how investors view its long term business mix. 📊 Keep an eye on CAR T treatment volumes, new center activations, and any disclosure on revenue tied to cell and gene therapy logistics. ⚠️ The main flagged risk is that debt is not well covered by operating cash flow. Investors may want to watch leverage and cash generation as capital needs evolve.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Cencora analysis. Alternatively, you can check out the community page for Cencora to see how other investors believe this latest news will impact the company's narrative.

Story Continues

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include COR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Wir untersuchen die relative Leistung von Elevance Health (NYSE:ELV) und seinen Peers, während wir uns der abgeschlossenen Q1-Ergebnisse der Gesundheitsversicherer widmen. Die Vordergrundprämien der Gesundheitsversicherer führen zu verlässlicher Umsatz, aber die Rentabilität hängt letztlich von genauen Risikoausschätzungen und der Fähigkeit ab, medizinische Kosten unter Kontrolle zu halten. Gesundheitsversicherer sind auch sehr empfindlich gegenüber regulatorischen Änderungen und wirtschaftlichen Bedingungen wie Arbeitslosigkeit. Im Gegenwartsbereich stehen dem Sektor Winden von einem alternden Bevölkerung, steigendem Bedarf an personalisierten Gesundheitsdienstleistungen und Fortschritten in der Datenanalyse zur Verbesserung des Kostenmanagements zur Verfügung. Allerdings könnten fortgesetzte regulatorische Überwachung von Preispraktiken, potenzielle Regierungsreformen wie erweiterte öffentliche Gesundheitsdienstleistungen und Inflation in medizinischen Kosten die Margen erhöhen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenarbeit zielt darauf ab, den Zugang zu Therapien zu erleichtern, während Kite sein Netzwerk an Behandlungszentren erweitert. Cencora unterstützt die Verteilung von Kites FDA-genehmigten CAR-T-Zell-Therapien Yescarta und Tecartus. Die Zusammenarbeit soll den Zugang zu Zelltherapien bei wachsendem Netzwerk an autorisierten Behandlungszentren in den USA erleichtern, einschließlich Gesundheitssystemen und Gemeinschafts-Onkologie-Praxen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die besten-performierenden Aktien haben typischerweise robuste Umsatzwachstum, steigende Margen und steigende Renditen auf das Kapital. Diejenigen, die dies Jahr für Jahr halten können, werden oft zu den Legenden des Investierens.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Gesundheitsunternehmen haben dieses Wochenende starke Ergebnisse präsentiert, wobei 18 von 20 Unternehmen ihre EPS-Schätzungen übertroffen und 15 ihre Umsatzerwartungen überboten haben. Die resiliente Nachfrage in der Pharmabranche, Gesundheitsdienstleistungen, medizinischen Geräten und Lebenswissenschaften hat die Druckpunkte bei Margen und Kostenerstattung ausgeglichen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Cencora COR wird am 6. Mai vor Markteröffnung die zweite Quartalsergebnisse 2026 bekanntgeben. Im letzten Quartal übertraf das Unternehmen mit einem Überraschungseffekt von 0,25% die Erwartungen. Die Earnings Surprise betrug im Durchschnitt der vier vorherigen Quartale 3,93%. Für das zweite Quartal werden eine Umsatzsteigerung um 7% und ein Gewinn pro Aktie von 4,81 US-Dollar erwartet. Cencora hat in diesem Jahr bislang 10,1% verloren, während die Branche 11,9% abgesunken ist. Der S&P-Index stieg hingegen um 6,4%. Die Umsatzsteigerung wird durch den Wachstumsmarkt für Spezialpharmazeutika und die Stärke des Kerngeschäfts in den USA unterstützt. Die Ergebnisse werden jedoch auch von negativen Faktoren beeinflusst, wie der Verlust eines großen Onkologie-Kunden und einer vorher abgestellten Kunden aus dem Lebensmittelbereich.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Some large-cap stocks are past their peak, and StockStory is here to help you separate the winners from the laggards. Keeping that in mind, here are two S&P 500 stocks leading the market forward and one that may struggle.

One Stock to Sell:

Home Depot (HD)

Market Cap: $328.2 billion

Founded and headquartered in Atlanta, Georgia, Home Depot (NYSE:HD) is a home improvement retailer that sells everything from tools to building materials to appliances.

Why Are We Wary of HD?

Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 1.5% for the last three years Poor same-store sales performance over the past two years indicates it’s having trouble bringing new shoppers into its brick-and-mortar locations Gross margin of 33.4% is below its competitors, leaving less money for marketing and promotions

Home Depot is trading at $329.90 per share, or 21.9x forward P/E. To fully understand why you should be careful with HD, check out our full research report (it’s free).

Two Stocks to Buy:

Cencora (COR)

Market Cap: $61.79 billion

Formerly known as AmerisourceBergen until its 2023 rebranding, Cencora (NYSE:COR) is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while offering logistics, data analytics, and consulting services.

Why Is COR a Good Business?

Unparalleled scale of $325.8 billion in revenue enables it to spread administrative costs across a larger membership base Share repurchases have amplified shareholder returns as its annual earnings per share growth of 14.5% exceeded its revenue gains over the last five years Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures

Cencora’s stock price of $317.62 implies a valuation ratio of 17.6x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.

Marsh & McLennan (MRSH)

Market Cap: $83.21 billion

With roots dating back to 1871 and a presence in over 130 countries, Marsh & McLennan (NYSE:MRSH) is a global professional services firm that helps organizations manage risk, strategy, and workforce challenges through its four specialized businesses.

Story Continues

Why Are We Backing MRSH?

Annual revenue growth of 9.4% over the last five years was superb and indicates its market share increased during this cycle Massive revenue base of $26.98 billion makes it a well-known name that influences purchasing decisions Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends, and its recently improved profitability means it has even more resources to invest or distribute

At $170.50 per share, Marsh & McLennan trades at 16.7x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

This dynamic can trouble even the most skilled investors, but luckily for you, we started StockStory to help you navigate these trade-offs and uncover exceptional companies that break the mold. That said, here is one large-cap stock with attractive long-term potential and two whose existing offerings may be tapped out.

Two Large-Cap Stocks to Sell:

Target (TGT)

Market Cap: $53.79 billion

With a higher focus on style and aesthetics compared to other large general merchandise retailers, Target (NYSE:TGT) serves the suburban consumer who is looking for a wide range of products under one roof.

Why Do We Pass on TGT?

Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations Widely-available products (and therefore stiff competition) result in an inferior gross margin of 28.1% that must be offset through higher volumes Subpar operating margin of 5.1% constrains its ability to invest in process improvements or effectively respond to new competitive threats

At $118.40 per share, Target trades at 14.9x forward P/E. Dive into our free research report to see why there are better opportunities than TGT.

Sherwin-Williams (SHW)

Market Cap: $77.69 billion

Widely known for its success in the paint industry, Sherwin-Williams (NYSE:SHW) is a manufacturer of paints, coatings, and related products.

Why Are We Cautious About SHW?

Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 1.1% for the last two years Demand will likely be soft over the next 12 months as Wall Street’s estimates imply tepid growth of 4.2% Earnings per share lagged its peers over the last two years as they only grew by 5.2% annually

Sherwin-Williams’s stock price of $315.90 implies a valuation ratio of 26.5x forward P/E. To fully understand why you should be careful with SHW, check out our full research report (it’s free).

One Large-Cap Stock to Buy:

Cencora (COR)

Market Cap: $60.29 billion

Formerly known as AmerisourceBergen until its 2023 rebranding, Cencora (NYSE:COR) is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while offering logistics, data analytics, and consulting services.

Why Will COR Outperform?

Dominant market position is represented by its $325.8 billion in revenue, which gives it negotiating power over membership pricing and reimbursement rates Share repurchases over the last five years enabled its annual earnings per share growth of 14.5% to outpace its revenue gains Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures

Story Continues

Cencora is trading at $308.68 per share, or 17.5x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 112 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.

This Week’s Ratings Changes:

Upgraded: Strong to Very Strong

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AMAT Applied Materials, Inc. A B A APA APA Corporation A C A BWXT BWX Technologies, Inc. A B A CACI CACI International Inc Class A A C A CMI Cummins Inc. A C A DINO HF Sinclair Corporation A C A EME EMCOR Group, Inc. A B A GOOG Alphabet Inc. Class C A B A HTHT H World Group Limited Sponsored ADR A B A JBL Jabil Inc. A B A LMT Lockheed Martin Corporation A B A MPC Marathon Petroleum Corporation A B A MTSI MACOM Technology Solutions Holdings, Inc. A B A NVMI Nova Ltd. A C A NVT nVent Electric plc A B A VIK Viking Holdings Ltd A B A WDS Woodside Energy Group Ltd Sponsored ADR A B A XOM Exxon Mobil Corporation A C A

Downgraded: Very Strong to Strong

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AGI Alamos Gold Inc. B A B APH Amphenol Corporation Class A A B B BIP Brookfield Infrastructure Partners L.P. A B B CLH Clean Harbors, Inc. A C B CNP CenterPoint Energy, Inc. A C B COR Cencora, Inc. A C B DG Dollar General Corporation A B B DTM DT Midstream, Inc. A C B FNV Franco-Nevada Corporation B B B GFI Gold Fields Limited Sponsored ADR A B B IX ORIX Corporation Sponsored ADR A B B MCK McKesson Corporation A C B NTR Nutrien Ltd. A C B UTHR United Therapeutics Corporation A C B VTR Ventas, Inc. A B B

Upgraded: Neutral to Strong

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade COP ConocoPhillips B D B CQP Cheniere Energy Partners, L.P. B B B CTRA Coterra Energy Inc. B C B DAL Delta Air Lines, Inc. B C B GMED Globus Medical Inc Class A B B B HLT Hilton Worldwide Holdings Inc. B D B IHG InterContinental Hotels Group PLC Sponsored ADR B C B LH Labcorp Holdings Inc. B C B LNG Cheniere Energy, Inc. B B B LVS Las Vegas Sands Corp. B B B MAR Marriott International, Inc. Class A B D B MRNA Moderna, Inc. B C B MS Morgan Stanley B B B NIO NIO Inc. Sponsored ADR Class A B B B NUE Nucor Corporation B C B PSTG Everpure, Inc. Class A C B B RDDT Reddit, Inc. Class A C B B TPL Texas Pacific Land Corporation B C B

Downgraded: Strong to Neutral

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AEE Ameren Corporation B C C AGNC AGNC Investment Corp. C B C ALNY Alnylam Pharmaceuticals, Inc C C C ARGX argenx SE Sponsored ADR C C C BUD Anheuser-Busch InBev SA/NV Sponsored ADR C C C COST Costco Wholesale Corporation C C C CVS CVS Health Corporation C B C ELS Equity LifeStyle Properties, Inc. C C C IRM Iron Mountain, Inc. C C C JBS JBS N.V. Class A C C C LLY Eli Lilly and Company C B C LYV Live Nation Entertainment, Inc. B D C MLM Martin Marietta Materials, Inc. B D C MSI Motorola Solutions, Inc. C C C NLY Annaly Capital Management, Inc. C B C NWG NatWest Group Plc Sponsored ADR C B C PM Philip Morris International Inc. B C C REG Regency Centers Corporation C B C RIVN Rivian Automotive, Inc. Class A B D C TKO TKO Group Holdings, Inc. Class A B D C TLN Talen Energy Corp B D C UL Unilever PLC Sponsored ADR C C C WEC WEC Energy Group Inc B C C

Upgraded: Weak to Neutral

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AEG Aegon Ltd. Sponsored ADR D C C AIZ Assurant, Inc. C C C ARM ARM Holdings PLC Sponsored ADR C C C COF Capital One Financial Corp D C C DECK Deckers Outdoor Corporation D B C DXCM DexCom, Inc. D B C ENTG Entegris, Inc. C C C FTV Fortive Corp. D C C IR Ingersoll Rand Inc. D C C ISRG Intuitive Surgical, Inc. D C C NXPI NXP Semiconductors NV D C C TFC Truist Financial Corporation C C C TU TELUS Corporation C D C WSM Williams-Sonoma, Inc. C C C

Downgraded: Neutral to Weak

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade ADSK Autodesk, Inc. D B D AMT American Tower Corporation D C D AZO AutoZone, Inc. D D D BDX Becton, Dickinson and Company D C D BJ BJ's Wholesale Club Holdings, Inc. D C D CTAS Cintas Corporation D C D EXR Extra Space Storage Inc. D C D FMS Fresenius Medical Care AG Sponsored ADR D B D HDB HDFC Bank Limited Sponsored ADR F C D LOW Lowe's Companies, Inc. D D D MSFT Microsoft Corporation D B D PSA Public Storage D C D PTC PTC Inc. D B D RBLX Roblox Corp. Class A D C D RDY Dr. Reddy's Laboratories Ltd. Sponsored ADR D C D RSG Republic Services, Inc. D C D SCI Service Corporation International D C D SJM J.M. Smucker Company D C D TSN Tyson Foods, Inc. Class A D D D TTWO Take-Two Interactive Software, Inc. D B D

Upgraded: Very Weak to Weak

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade Z Zillow Group, Inc. Class C F C D

Downgraded: Weak to Very Weak

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AMH American Homes 4 Rent Class A F C F BEKE KE Holdings, Inc. Sponsored ADR Class A F D F MKC McCormick & Company, Incorporated F C F

To stay on top of my latest stock ratings, plug your holdings into Stock Grader, my proprietary stock screening tool. But, you must be a subscriber to one of my premium services.

Story Continues

To learn more about my premium service, Growth Investor, and get my latest picks, go here. Or, if you are a member of one of my premium services, you can go here to get started.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Sincerely,An image of a cursive signature in black text.

Louis Navellier

Editor, Market 360

The post ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks appeared first on InvestorPlace.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

U.S. stocks ended Friday broadly lower, with selling pressure intensifying across sectors as investors weighed persistent geopolitical risks tied to tensions in the Middle East.

The tech-focused Nasdaq Composite was -2%. At the same time, the benchmark S&P 500 was -1.5%, and the blue-chip Dow was -1.6%.

However, the S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained about 0.67% during the week.

The top S&P 500 healthcare gainers and losers for the last week are as follows:

TOP GAINERS:

Merck & Co. (MRK [https://seekingalpha.com/symbol/MRK]) +4.77%

Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +3.62%

DaVita (DVA [https://seekingalpha.com/symbol/DVA]) +3.43%

West Pharmaceutical Services (WST [https://seekingalpha.com/symbol/WST]) +2.67%

Mettler-Toledo International (MTD [https://seekingalpha.com/symbol/MTD]) +2.29%

TOP LOSERS:

Insulet Corporation (PODD [https://seekingalpha.com/symbol/PODD]) -8.33%

Centene (CNC [https://seekingalpha.com/symbol/CNC]) -7.03%

DexCom (DXCM [https://seekingalpha.com/symbol/DXCM]) -7.02%

UnitedHealth Group (UNH [https://seekingalpha.com/symbol/UNH]) -6.01%

Intuitive Surgical (ISRG [https://seekingalpha.com/symbol/ISRG]) -5.30%

Here are some of the important healthcare stories from this week:

MERCK ACQUIRES TERNS PHARMA FOR $6.7B

Merck (MRK [https://seekingalpha.com/symbol/MRK]) on Wednesday said [https://seekingalpha.com/news/4568378-merck-to-acquire-terns-pharmaceuticals-for-53-per-share-in-cash] it will acquire clinical-stage biotech Terns Pharmaceuticals (TERN [https://seekingalpha.com/symbol/TERN]) in an all-cash deal valued at approximately $6.7 billion. Merck will pay $53.00 per share, representing a significant premium over Terns' recent trading average, as it seeks to integrate the promising leukemia candidate TERN-701 into its hematology portfolio.

The transaction is expected to be accounted for as an asset acquisition and close in the second quarter of 2026, resulting in a charge of approximately $5.8 billion, or approximately $2.35 per share, included in both second-quarter and full-year 2026 GAAP and non-GAAP results, Merck (MRK [https://seekingalpha.com/symbol/MRK]) said in a statement [https://seekingalpha.com/pr/20450324-merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-ternminus#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews].

Merck (MRK [https://seekingalpha.com/symbol/MRK]) has been pursuing deals to strengthen its pipeline, with CEO Rob Davis spearheading a strategy to diversify the company's portfolio ahead of the 2028 patent expiration for its blockbuster cancer drug, Keytruda.

Under the terms of the merger agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Terns.

MEDTRONIC LOWERS 2026 EARNINGS OUTLOOK ON RECENT MINIMED UPDATES

Medtronic (MDT [https://seekingalpha.com/symbol/MDT]) cut [https://seekingalpha.com/news/4568410-medtronic-cuts-earnings-outlook-minimed-updates] its full-year earnings outlook, citing the recent IPO of its diabetes business, MiniMed Group (MMED [https://seekingalpha.com/symbol/MMED]), and the earlier-than-expected FDA approval and commercial launch of MiniMed Flex, a next-generation insulin pump, last week.

In an SEC filing on Tuesday, the MedTech giant disclosed that the public listing of 10% of its holding in MiniMed (MMED [https://seekingalpha.com/symbol/MMED]) is expected to c [https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=319897440&type=HTML&symbol=MDT&cdn=fb54ec5d65c7acdae880ad37cdd57ecb&companyName=Medtronic+plc.&formType=8-K&dateFiled=2026-03-24]reate a roughly $0.02 per share headwind to Medtronic (MDT [https://seekingalpha.com/symbol/MDT]) shareholders for each month of the quarter following the closure of the IPO on Mar. 9. [https://seekingalpha.com/news/4561982-medtronics-diabetes-unit-minimed-drops-ipo#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]

As a result of the IPO, the company projects a total dilutive effect of $0.04 per share for Q4 fiscal 2026, ending on April 24.

Additionally, the company projects a $0.08 per share impact on its Q4 FY26 results, as MiniMed (MMED [https://seekingalpha.com/symbol/MMED]) is set to recognize a one-time charge of $157M to account for a series of payments due to Blackstone (BX [https://seekingalpha.com/symbol/BX]), which helped fund the development of MiniMed Flex. [https://seekingalpha.com/news/4565819-minimed-gets-fda-clearance-for-minimed-flex-its-smallest-smartphone-controlled-insulin-pump#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]

As a result of the above changes, Medtronic (MDT [https://seekingalpha.com/symbol/MDT]) now estimates its non-GAAP earnings per share for fiscal 2026 to reach $5.50 - $5.54 compared to $5.62 - $5.66 in its prior guidance and $5.62 in the consensus. The outlook of high single-digit EPS growth for fiscal 2027 remains unchanged.

SAREPTA GAINS ON DATA FOR MUSCULAR DYSTROPHY THERAPIES

Sarepta Therapeutics (SRPT [https://seekingalpha.com/symbol/SRPT]) added [https://seekingalpha.com/news/4568547-sarepta-posts-data-muscular-dystrophy-drugs] ~35% on Wednesday after the company posted initial data from Phase 1/2 trials for its experimental drugs targeted at two rare forms of muscular dystrophies.

The company said that the results support the potential of SRP-1001 and SRP-1003, which are based on its small interfering RNA (siRNA) treatment platform. The treatments are designed to treat facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1), respectively.

According to Sarepta (SRPT [https://seekingalpha.com/symbol/SRPT]), the results indicate that its αvβ6 integrin-targeted siRNA approach can lead to high muscle exposure of targeted treatments without dose-limiting toxicities.

While RNA-targeted therapies have shown promise against FSHD and DM1, their efficacy has been limited due to rapid degradation inside the body before delivery to intended cells.

“We are pleased that these early clinical results showed high levels of siRNA delivery to muscle, with no saturation of muscle siRNA uptake or dose-limiting safety signals to date,” said Louise Rodino-Klapac, Serepta’s (SRPT [https://seekingalpha.com/symbol/SRPT]) President of R&D and technical operations. [https://seekingalpha.com/pr/20450629-sarepta-announces-first-clinical-data-from-sirna-pipeline-targeting-fshd1-and-dm1#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]

NOVARTIS TO BUY EXCELLERGY FOR UP TO $2B TO BOOST ALLERGY PORTFOLIO

Novartis (NVS [https://seekingalpha.com/symbol/NVS]) said [https://seekingalpha.com/news/4569684-novartis-to-buy-excellergy-for-up-to-2b] it will acquire U.S. biotech firm Excellergy for up to $2B in upfront and milestone payments, in a move to strengthen its allergy portfolio.

The deal, which is expected to close in the second half of the year, will add Excellergy's drug candidate that's currently in early-stage trials to Novartis' (NVS [https://seekingalpha.com/symbol/NVS]) portfolio.

The drug, called Exl-111, is a trifunctional Effector Cell Response Inhibitor designed to treat certain allergic disorders.

If confirmed clinically, Exl-111's mechanism could support earlier symptom relief, stronger disease control, more convenient dosing and broader use across food allergy, allergic asthma and other IgE-driven diseases.

GILEAD TO ACQUIRE OURO MEDICINES IN $1.68B DEAL TO ADVANCE AUTOIMMUNE T CELL THERAPIES

Gilead Sciences (GILD [https://seekingalpha.com/symbol/GILD]) on Monday said [https://seekingalpha.com/news/4567650-gilead-sciences-to-buy-ouro-medicines-to-boost-t-cell-therapy-for-autoimmune-diseases] it would acquire privately held Ouro Medicines, a biotech company developing T cell engager therapies for autoimmune diseases. The agreement includes $1.675 billion in upfront cash, plus up to $500 million in potential milestone payments.

CENCORA TO BUY EYESOUTH PARTNERS’ RETINA BUSINESS FOR $1.1B

Medical distributor Cencora (COR [https://seekingalpha.com/symbol/COR]) signed [https://seekingalpha.com/news/4567721-cencora-buy-eyesouth-partners-retina-business] an agreement to acquire EyeSouth Partners’ retina business for $1.1B through its eye care subsidiary, Retina Consultants of America, marking its latest deal-making activity.

The company expects the transaction, adjusted for financing costs, to slightly boost its adjusted diluted EPS in the first twelve months after the deal closure. However, Cencora (COR [https://seekingalpha.com/symbol/COR]) said its reaffirmed outlook for fiscal 2026 doesn’t expect the deal to close within this fiscal year. [https://seekingalpha.com/pr/20446788-cencora-to-expand-retina-consultants-of-america-through-acquisition-of-eyesouth-partners#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]

MORE ON STATE STREET HEALTH CARE SELECT SECTOR SPDR ETF

* Routine Vaccines Okay For Now: Investment Implications Of The Court Decision [https://seekingalpha.com/article/4883587-routine-vaccines-okay-for-now-investment-implications-of-the-court-decision]
* Sector Rotation: Healthcare XLV Should Be The Next Stop [https://seekingalpha.com/article/4875728-sector-rotation-healthcare-xlv-should-be-the-next-stop]
* VT: Still The Best Approach To Passive Investing [https://seekingalpha.com/article/4872902-vt-still-the-best-approach-to-passive-investing]
* Humana is the worst performing large-cap healthcare stock YTD [https://seekingalpha.com/news/4569881-humana-is-the-worst-performing-large-cap-healthcare-stock-ytd]
* Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B [https://seekingalpha.com/news/4568744-indivior-liquidia-crinetics-top-quant-pharma-list-as-merck-scoops-up-terns-for-67b]